BofA Lowers Medtronic Price Target on Inflation and Utilization Concerns

Key Facts

1Bank of America reduced its price target on Medtronic stock to $95 from $110 while maintaining a Buy rating.

2Goldman Sachs maintained a Hold rating on MDT, noting a balanced risk-reward profile.

In a move reflecting growing caution within the med-tech sector, Bank of America reduced its price target for Medtronic (MDT) to $95 from $110 while maintaining a Buy rating. The adjustment stems from concerns over lower utilization rates and the persistent impact of inflation on 2027 estimates, despite current top-line momentum. Meanwhile, Goldman Sachs maintained a Hold rating on the stock, citing a balanced risk-reward profile for the medical device giant.

This valuation shift occurs as the healthcare sector navigates mixed headwinds; Medtronic's most recent quarterly results showed organic revenue growth of 5.2%, slightly outperforming peers like Abbott Laboratories which saw 4.5% growth in medical sales per market data. However, industry analysts note that rising labor and raw material costs continue to threaten operating margins for complex supply chain manufacturers, justifying the more conservative long-term outlook for the 2027 fiscal period.

MDT shares stood at $80.20 at close June 12, 2026, trading within a tight daily range of $79.26 to $80.74 per market data. Traders should look toward the upcoming U.S. CPI inflation data on June 10, 2026, as a critical catalyst, given its potential impact on operating cost assumptions and the broader interest rate environment affecting healthcare equity valuations.